| Bioactivity | SRTCX1003 is an orally active SIRT1 activator. SRTCX1003 suppresses inflammatory responses[1]. |
| Target | SIRT1 |
| Invitro | SRTCX1003 (0-10 μM; 24 h) 剂量依赖性降低 U2OS 细胞中乙酰化 p65 蛋白[1]。SRTCX1003 (5 μM; 6 h) 减弱 HEK 293T/17 细胞中 TNFα 诱导的 p65 乙酰化[1]。SRTCX1003 (0-100 μM; 2 h) 剂量依赖性减少 RAW 细胞中 LPS (HY-D1056) 诱导的 TNFα 分泌[1]。 Western Blot AnalysisHEK 293T/17 Cell Line: |
| In Vivo | SRTCX1003 (3-100 mg/kg; oral; once) 在小鼠炎症模型中降低 LPS (HY-D1056) 刺激的 TNFα 和 IL-12p40 的产生[1]。 Animal Model: |
| Name | SRTCX1003 |
| CAS | 1203480-86-7 |
| Formula | C23H23N5O3S |
| Molar Mass | 449.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yang H, et al. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity. |